Alexion Pharmaceuticals (ALXN) CFO Successor Is A Strong Replacement - RBC
September 18, 2019 8:27 AM
RBC Capital analyst Kennen MacKay reiterated an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN) after the company announced the planned ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
